DIRAS3

{{Short description|Mammalian protein found in Homo sapiens}} {{Infobox_gene}} '''GTP-binding protein Di-Ras3''' (DIRAS3) also known as '''aplysia ras homology member I''' (ARHI) is a protein that in humans is encoded by the DIRAS3 gene.<ref name="entrez">{{cite web | title = Entrez Gene: DIRAS family, GTP-binding RAS-like 3 | url = https://www.ncbi.nlm.nih.gov/gene/9077 }}</ref>

This gene is a member of the Ras superfamily and is expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers. It is a maternally imprinted gene, with monoallelic expression of the paternal allele, which is associated with growth suppression. Thus, this gene appears to be a putative tumor suppressor gene whose function is abrogated in ovarian and breast cancers.<ref name="entrez"/>

DIRAS3 is linked to breast cancer as well as ovarian cancer. The ''DIRAS3'' gene includes one promoter, two exons and one intron with a 687 bp protein-coding region that encodes a 26-kDa protein.<ref name="yang">{{cite journal | vauthors = Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T | title = NOEY2 mutations in primary breast cancers and breast hyperplasia | journal = Breast | volume = 18 | issue = 3 | pages = 197–203 | date = Jun 2009 | pmid = 19482475 | doi = 10.1016/j.breast.2009.04.004 | doi-access = free }}</ref> The DIRAS3 protein is a GTPase belonging to the Ras superfamily and shares 50–60% homology with Ras and Rap, two other small GTP binding proteins.<ref name="yang" /> Reduced expression of DIRAS3 has been reported in 70% of invasive breast cancers.<ref name="yuan">{{cite journal | vauthors = Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y | title = Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers | journal = Cancer Research | volume = 63 | issue = 14 | pages = 4174–80 | date = Jul 2003 | pmid = 12874023 }}</ref>

== Structure and function ==

While ARHI is structurally similar to other GTPase proteins, its function is remarkably different from Ras. Ras is an oncogenic protein involved in cellular proliferation and signal transduction, and while the Ras superfamily generally consists of positive growth regulators, ''ARHI'' is a tumor-suppressor gene. In contrast to Ras, ARHI works as an inhibitor for cell growth, thus functioning as a negative growth regulator. ARHI has also been shown to have less GTPase activity than most Ras proteins even though the proteins share a very similar structure.<ref name="luo">{{cite journal | vauthors = Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC | title = ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers | journal = Oncogene | volume = 22 | issue = 19 | pages = 2897–909 | date = May 2003 | pmid = 12771940 | doi = 10.1038/sj.onc.1206380 | doi-access = free }}</ref>

The underlying cause for these dramatic differences in function is thought to be structural variations between ARHI and the Ras superfamily. The negative growth regulation exhibited by ARHI is most likely due to a unique 34-amino-acid N-terminus extension. This sequence is not generally found in the Ras superfamily, most of which show no inhibitory activity towards cell growth and even act as positive growth regulators. Deletion of this tail results in a significant drop in ARHI's ability to inhibit cell growth. This change in structure has no effect on protein expression levels or its GTP-binding ability, suggesting the extension's primary function is giving rise to this protein's negative growth regulation.

The reduced GTPase activity observed in ARHI is thought{{By whom|date=June 2014}} to arise from critical differences in three specific amino acid residues in the effector domain. These residues are highly conserved in other Ras proteins, and are critical for the GTPase activity. In Ras, they are specifically G12, A59, and Q61. ARHI has three different amino acids in the effector domain: A46, K93, and G95. While ARHI still binds GTP with high affinity, its hydrolysis of GTP to GDP is relatively low because of these differences.

== Role in cancer ==

While ARHI is constitutively expressed in normal ovarian and breast epithelial cells, it is absent in cancers found in these tissues where no expression of ARHI has been detected.<ref name="yinhua">{{cite journal | vauthors = Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC | title = NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 1 | pages = 214–9 | date = Jan 1999 | pmid = 9874798 | pmc = 15119 | doi = 10.1073/pnas.96.1.214 | bibcode = 1999PNAS...96..214Y | doi-access = free }}</ref> In non-cancerous cells growth factor signals associate ARHI N- and C-terminally to the plasma membrane, where it can interact with C-RAF. This interaction inhibits the activation of MEK and ERK and even cell migration.<ref name="Klingauf">{{cite journal | vauthors = Klingauf M, Beck M, Berge U, Turgay Y, Heinzer S, Horvath P, Kroschewski R | title = The tumour suppressor DiRas3 interacts with C-RAF and downregulates MEK activity to restrict cell migration | journal = Biology of the Cell | volume = 105 | issue = 2 | pages = 91–107 | date = Nov 2012 | doi = 10.1111/boc.201200030 | pmid = 23157514 | s2cid = 19790001 }}</ref> In cancer tissues, where ARHI is not expressed, cells will thus migrate; this possibly is a cause for metastasis especially in breast cancer.

ARHI influences also the cell cycle, specifically ARHI's strong inhibition of the cyclin D1 promoter.<ref name="yinhua" /> Cyclin D1 is an essential protein in the cell's progression from G1 to S phase, and its regulation by ARHI is critical in maintaining healthy cells. This is the mechanism by which ARHI inhibits cell growth and acts as a negative growth regulator. A loss of ARHI function could result in out-of-control cell growth and, in fact, cyclin D1 is often up-regulated in ovarian cancers and invasive breast carcinomas when ARHI is found to be down-regulated.<ref name="yinhua" /> When ''ARHI'' is introduced into cancer cells lacking this gene, many responses occur in addition to cyclin D1 down-regulation.<ref name="luo" /> These include induction of p21, activation of JNK, and reduced signaling through the Ras/MAP pathway.<ref name="luo" /> Thus, loss of any of these processes (arising from loss of ''ARHI'') can lead to cancer.

The "ARHI" gene is maternally imprinted (expressed monoallelically) and mapped specifically to 1p31, which is a common site for loss of heterozygosity (LOH). This locus on chromosome 1 is the most frequent deletion in breast and ovarian cancers. Because this gene is maternally imprinted, LOH of the nonimprinted allele (the paternal copy) confers a loss of ARHI expression. Although LOH has been reported in 40% of ovarian and breast cancers, another typical mechanism of gene silencing is through methylation. Since ARHI expression is decreased in 70% of invasive breast cancer, aberrant methylation is almost certainly the other common mechanism through which the gene is silenced.<ref name="yuan" /> Found in "ARHI" are three CpG islands, which are common sites of epigenetic regulation, and hypermethylation of these regions in other tumor suppressor genes have been observed in various cancers. For example, decreased expression of BRCA1 in cancerous tissue has been linked with hypermethylation of the "BRCA1" promoter.<ref name="yuan" /> Indeed, hypermethylation of certain CpG islands were associated with decreased expression of ARHI, and the protein showed a corresponding re-expression after demethylation of the regions.<ref name="yuan" />

Because the gene is imprinted, the two-hit tumorigenesis model proposed by Knudson is reduced to a more susceptible situation. The nonexpression of the maternal allele leaves the gene only one “strike” in terms of any number of mutational mechanisms, the two most common being LOH and hypermethylation of the gene promoter.<ref name="yuan" /> In this way, the imprinted "ARHI" gene has a high risk of conferring cancers due to its susceptibility to mutations and epigenetic modifications.

== References == {{Reflist|33em}}

== Further reading == {{refbegin | 2}} * {{cite journal | vauthors = Baljuls A, Beck M, Oenel A, Robubi A, Kroschewski R, Hekman M, Rudel T, Rapp UR | title = The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF | journal = The Journal of Biological Chemistry | volume = 287 | issue = 27 | pages = 23128–40 | date = Jun 2012 | pmid = 22605333 | pmc = 3391090 | doi = 10.1074/jbc.M112.343780 | doi-access = free }} * {{cite journal | vauthors = Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y | title = Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers | journal = Cancer Research | volume = 63 | issue = 14 | pages = 4174–80 | date = Jul 2003 | pmid = 12874023 }} * {{cite journal | vauthors = Lu X, Qian J, Yu Y, Yang H, Li J | title = Expression of the tumor suppressor ARHI inhibits the growth of pancreatic cancer cells by inducing G1 cell cycle arrest | journal = Oncology Reports | volume = 22 | issue = 3 | pages = 635–40 | date = Sep 2009 | pmid = 19639215 | doi=10.3892/or_00000483| doi-access = free }} * {{cite journal | vauthors = Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC | title = NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 96 | issue = 1 | pages = 214–9 | date = Jan 1999 | pmid = 9874798 | pmc = 15119 | doi = 10.1073/pnas.96.1.214 | bibcode = 1999PNAS...96..214Y | doi-access = free }} * {{cite journal | vauthors = Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T | title = NOEY2 mutations in primary breast cancers and breast hyperplasia | journal = Breast | volume = 18 | issue = 3 | pages = 197–203 | date = Jun 2009 | pmid = 19482475 | doi = 10.1016/j.breast.2009.04.004 | doi-access = free }} * {{cite journal | vauthors = Pei XH, Yang Z, Liu HX, Qiao SS | title = Aplasia Ras homologue member I overexpression induces apoptosis through inhibition of survival pathways in human hepatocellular carcinoma cells in culture and in xenograft | journal = Cell Biology International | volume = 35 | issue = 10 | pages = 1019–24 | date = Oct 2011 | pmid = 21933150 | doi = 10.1042/CBI20110023 | s2cid = 12811622 }} * {{cite journal | vauthors = Shi Z, Zhou X, Xu L, Zhang T, Hou Y, Zhu W, Zhang T | title = [NOEY2 gene mRNA expression in breast cancer tissue and its relation to clinicopathological parameters] | journal = Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] | volume = 24 | issue = 5 | pages = 475–8 | date = Sep 2002 | pmid = 12485503 }} * {{cite journal | vauthors = Li BX, Li J, Luo CL, Zhang MC, Li H, Li LL, Xu HF, Shen YW, Xue AM, Zhao ZQ | title = Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma | journal = Indian Journal of Experimental Biology | volume = 51 | issue = 3 | pages = 208–17 | date = Mar 2013 | pmid = 23678541 }} * {{cite journal | vauthors = Janssen EA, Øvestad IT, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP | title = LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer | journal = Cellular Oncology | volume = 31 | issue = 5 | pages = 335–43 | year = 2009 | pmid = 19759414 | pmc = 4619107| doi = 10.3233/CLO-2009-0479 }} {{refend}}

== External links == * {{MeshName|NOEY2+protein,+human}}

Category:Genes on human chromosome 1